Afatinib combined with anlotinib in the treatment of lung adenocarcinoma patient with novel HER2 mutation: a case report and review of the literature

World J Surg Oncol. 2021 Nov 18;19(1):330. doi: 10.1186/s12957-021-02444-7.

Abstract

Background: HER2 is a member of the ERBB family of receptor tyrosine kinases, and HER2 mutations occur in 1-4% of non-small cell lung cancer (NSCLC) as an oncogenic driver mutation. We found a rare mutation of HER2 p.Asp769Tyr in NSCLC.

Case presentation: We presented a case of a 68-year-old nonsmoking male patient with brain metastasis from lung adenocarcinoma harboring a rare mutation of HER2 p.Asp769Tyr. After multiple lines of treatment, he obtained a durable response (10 months) to afatinib and anlotinib.

Conclusion: We reported for the first time that afatinib and anlotinib have successfully treated lung adenocarcinoma with HER2 p.Asp769Tyr mutation. This finding can provide an insight into the optimal treatment of lung adenocarcinoma patients with novel mutations. Additionally, we summarized the efficacy of targeted therapy for HER2 mutant lung cancer in this article.

Keywords: Afatinib; Anlotinib; HER2 mutation; Lung adenocarcinoma; Targeted therapy.

Publication types

  • Case Reports
  • Review

MeSH terms

  • Adenocarcinoma of Lung* / drug therapy
  • Adenocarcinoma of Lung* / genetics
  • Afatinib / therapeutic use
  • Aged
  • Carcinoma, Non-Small-Cell Lung* / drug therapy
  • Carcinoma, Non-Small-Cell Lung* / genetics
  • Humans
  • Indoles
  • Lung Neoplasms* / drug therapy
  • Lung Neoplasms* / genetics
  • Male
  • Mutation
  • Prognosis
  • Protein Kinase Inhibitors
  • Quinolines
  • Receptor, ErbB-2 / genetics

Substances

  • Indoles
  • Protein Kinase Inhibitors
  • Quinolines
  • anlotinib
  • Afatinib
  • ERBB2 protein, human
  • Receptor, ErbB-2